MEDI 500

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMEDI 500
Drug Alias NameG 022Anti-TCR-alphabeta monoclonal antibody T10B9T-10B9T12A10T10B9.1A31 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsImmunosuppressants
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsRejection of renal transplantationGraft vs Host DiseaseRejection in heart transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Kentucky Chandler Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune Llc
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantationGraft vs Host DiseaseRejection in heart transplantation

Other Information

ATC CodeN/A
Related LinksN/A